What We Can Learn From Bill Ackman Walking Away From Valeant Pharmaceuticals Intl Inc.

Investors can learn a lot from Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX).

| More on:
The Motley Fool

Recently, it was announced that hedge fund manager Bill Ackman sold his firm’s entire stake in Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). By selling his final position, he has done what many investors hate to do: he locked in losses.

Almost every investor has at least one position in their portfolio that is held at a loss. When an investor enters a position and sees the investment decline in value by say 20%, it is important to understand what needs to happen for the investor to be able to recoup their original investment. Using very simple math, an investment of $100 which declines by 20% to $80 needs to return to $100 for the investor to be even.

Assuming we hit the reset button here, a new investor may purchase the shares at $80 and get a $20 return divided by the initial outlay of $80, which translates to a return of 25%, not 20%!

For investors holding positions that are slightly at a loss, the amount a stock must come back to make up the loss is nothing more than a rounding error. Once it gets beyond 20-25%, however, the numbers are a little more serious.

With a loss of 10% as an example, the return must be 10/90 = 11.1%, meaning a difference of 1.1% — a very minor number.

Valeant shares have declined close to 90% since Ackman made the initial investment, translating to a return of (90/10) = 900% for his firm to get back to even. Although we’ve seen the hedge fund manager do fantastic things in the past, any investor hoping for a return of 900% is dreaming.

The amount of interest expenses as a percentage of revenue is simply too high for this company to survive over the long term, translating to a desperate need to either drastically increase revenue or repay debt.

As it is difficult to increase revenues, the second option is to pay off debt. Debt is close to $30 billion, and that can only mean selling assets or doing a secondary share issue. The challenge with this possibility is that Valeant has $30 billion in debt but a market capitalization of only approximately $5 billion. If the float were to double, the debt would only be reduced by approximately 16.5% or so.

And it seems the company is in for the fight of a lifetime after losing one of the heavyweight members of the board of directors.

Although the company has many excellent products to offer consumers, the reality is, the debt burden is simply too much to carry at this point. Bankruptcy may take months from here, but it’s inevitable — the fat lady will sing!

Fool contributor Ryan Goldsman has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

dreaming of financial success
Bank Stocks

TD Bank Is My Top Canadian Dividend Stock and I’m Never Selling

TD Bank (TSX:TD) stock is a dividend hero that I wouldn't sell after the recent run.

Read more »

young people stare at smartphones
Tech Stocks

Here’s a TFSA Stock Yielding 0.4% With Reliable Quarterly Payments

Apple (NASDAQ:AAPL) has a small dividend, but it's growing steadily. After a strong device showcase, perhaps the best spot for…

Read more »

monthly calendar with clock
Investing

This 5.8% Dividend Stock Pays Cash Every Month (and There Are Other Reasons You Might Want to Own It)

CT REIT (TSX:CRT.UN) might be the retail REIT to buy as shares plunge and yields swell.

Read more »

A train passes Morant's curve in Banff National Park in the Canadian Rockies.
Dividend Stocks

This Isn’t a “Quick Win” Stock: It’s a “Steady Builder” One

CN Rail (TSX:CNR) may be the steadiest compounder on the entire Canadian stock market.

Read more »

dividend growth for passive income
Dividend Stocks

1 Undervalued Canadian Dividend Stock to Buy Now and Hold for Decades

This stock is down 15% from the recent highs and now offers an attractive dividend yield.

Read more »

Bottles and glasses of alcohol drinks
Investing

Trump’s Alcohol Ban Will Hit This Canadian Producer: What Corby Investors Need to Know

The strength of Corby’s domestic business has helped offset some of the potential weakness associated with U.S. exports.

Read more »

some investments are riskier than others
Investing

This Popular Income Strategy Promises Less Risk: Here’s What Investors Give Up

Covered-call ETFs like ZWC can pay high monthly cash flow, but the extra income comes from giving up some upside.

Read more »

The Meta Platforms logo displayed on a smartphone
Tech Stocks

1 Decision Today Could Change Your Financial Story

Contributing to and investing with your TFSA in names like Meta Platforms (NASDAQ:META) could change your long-term financial trajectory.

Read more »